Liminatus Pharma Inc. (LIMN)
LIMN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LIMN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001971387 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standards Board ( FASB ) ASC 205-40, Presentation of Financial Statements Going Concern , management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are " | 10-Q 2026-08-14 |
| Cash and burn | $3.0M cash; operating cash flow -$993K a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,343,207 (2026-08-14); 27,064,633 a year earlier. | Cover page 2026-08-14 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-08-21 | Source 2026-08-21 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 5 (8-K item 3.01) | 8-K 2026-08-18 |
| Auditor | WithumSmith+Brown, PC, Whippany, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.4M | -$970K | $3.0M | $1.4M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$1.1M | -$2.0M | $1.9M | $1.4M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$8.2M | -$387K | $338K | $1.4M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$1.8M | -$601K | $725K | $1.4M | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | $113K | -$8.8M | $1.3M | $1.4M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$328K | -$159K | $0 | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$230K | -$141K | $0 | $20.0M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$601K | -$206K | Not filed | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-06-24 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-11-03 |
| Latest proxy | DEF 14A | 2026-07-13 |
Source: SEC EDGAR submissions feed, 109 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +17.7% |
| 1 month | -12.3% |
| 3 months | -60.1% |
| Year to date | -90.2% |
| 1 year | -94.4% |
| From 52-week high | -97.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| LIMNW | Liminatus Pharma Inc. Warrants | $0.0351 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
| SNTI | Senti Biosciences Holdings Inc. | $0.1360 | -2.86% | $5.2M |
| VIVS | VivoSim Labs Inc. | $0.1237 | -2.68% | $2.5M |
| CLDI | Calidi Biotherapeutics Inc. | $0.6023 | -3.15% | $2.2M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier